StreetInsider
Log in to your account:
Log in
Signup
Home
EPS Insider
Event Calendar
Conferences
Classic Site
Upgrade to SI Premium - Free Trial
Sarepta Therapeutics (SRPT) Issues Publication of Positive Eteplirsen Phase 2b Long-Term Data in DMD
November 17, 2015 8:44 AM
Sarepta Therapeutics (Nasdaq: SRPT) announced that the Annals of Neurology published online [link to final article] positive efficacy and safety ...
(Premium-only article. Please sign in or upgrade to SI Premium to view.)
Categories
Corporate News
FDA
Management Comments
Next Articles
Buy Sarepta (SRPT) Into Kyndrisa Briefing Documents and Panel Outcome - Oppenheimer
November 19, 2015 3:28 PM
Baird Expects FDA Rejection for Drisapersen and Eteplirsen (BMRN) (SRPT)
November 19, 2015 8:18 AM
Sarepta Therapeutics Announces Publication of Positive Long-Term Safety and Efficacy Data for Eteplirsen in the Annals of Neurology
November 17, 2015 8:43 AM
